Inventor
MENRAD ANDREAS
DE26 patents
⚠️ This page may combine multiple inventors who share the name “MENRAD ANDREAS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SCHERING AG
12 patentsUS7129254B2Oct 31, 2006
Effector conjugates, process for their production and their pharmaceutical use
SCHERING AG51 citations95
US7002022B2Feb 21, 2006
N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF
SCHERING AG24 citations92
US6376480B1Apr 23, 2002
Vitamin D derivatives with substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agents
SCHERING AG18 citations92
US6372731B1Apr 16, 2002
Vitamin D derivatives with C-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments
SCHERING AG21 citations92
US6344339B1Feb 5, 2002
Monoclonal antibodies against the extracellular domain of human VEGF-receptor protein (KDR)
SCHERING AG23 citations89
US7429592B2Sep 30, 2008
Cyanoanthranilamide derivatives and the use thereof as medicaments
SCHERING AG12 citations84
US7202260B2Apr 10, 2007
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
SCHERING AG11 citations84
US7012081B2Mar 14, 2006
Anthranyl amides and their use as medicaments
SCHERING AG14 citations84
US7148357B2Dec 12, 2006
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
SCHERING AG15 citations83
US7459470B2Dec 2, 2008
N-oxide anthranylamide derivatives and their use as medicaments
SCHERING AG8 citations73
US7081468B2Jul 25, 2006
Ortho-substituted anthranilic acid amides and their use as medicaments
SCHERING AG8 citations73
US7335775B2Feb 26, 2008
Effector conjugates, process for their production and their pharmaceutical use
SCHERING AG5 citations61
NOVARTIS AG
5 patentsUS7122547B1Oct 17, 2006
Anthranilic acid amides and the use thereof as medicaments
NOVARTIS AG79 citations97
US6878720B2Apr 12, 2005
VEGF receptor tyrosine kinase inhibitors
NOVARTIS AG50 citations96
US6448277B2Sep 10, 2002
VEGF receptor tyrosine kinase inhibitors
NOVARTIS AG64 citations96
US6818661B2Nov 16, 2004
Anthranylalkyl and cycloalkyl amides and use thereof as VEGF receptor inhibitors
NOVARTIS AG21 citations92
US7479491B2Jan 20, 2009
Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors
NOVARTIS AG0 citations52
GENZYME CORP
2 patentsPHILOGEN SPA
2 patentsUS7851599B2Dec 14, 2010
Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine
PHILOGEN SPA10 citations77
US9289470B2Mar 22, 2016
Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
PHILOGEN SPA0 citations45